Nivolumab |
Topalian et al. [10] | 5H1 | Multiple | ≥5 % | 25 | 36 |
<5 % | 17 | 0 |
Gettinger et al. [11] | 28-8 | NSCLC | ≥5 % | 33 | 15 |
<5 % | 35 | 14 |
Rizvi et al. [13] | 28-8 | Squamous NSCLC | ≥5 % | 25 | 24 |
<5 % | 51 | 14 |
Brahmer et al. [14] | 28-8 | Squamous NSCLC | ≥5 % | 42 | 21 |
<5 % | 75 | 15 |
Borghaei et al. [15] | 28-8 | Non-squamous NSCLC | ≥5 % | 95 | 34 |
<5 % | 136 | 14 |
Hodi et al. [56] | 28-8 | Melanoma | ≥5 % | 18 | 44 |
<5 % | 23 | 13 |
Robert et al. [57] | 28-8 | Melanoma | ≥5 % | 74 | 53 |
<5 % or indet | 136 | 33 |
Weber et al. [58] | 28-8 | Melanoma (ipilimumab refractory) | ≥5 % | 55 | 44 |
<5 % | 64 | 20 |
Larkin et al. [59] | 28-8 | Melanoma | ≥5 % | 80 | 58 |
<5 % | 208 | 41 |
Pembrolizumab |
Garon et al. [16] | 22C3 | NSCLC | ≥50 % | 119 | 41 |
<50 % | 237 | 13 |
Herbst et al. [17] | 22C3 | NSCLC | ≥50 % | 290 | 30 |
1–49 % | 400 | 10 |
Kefford et al. [60] | 22C3 | Melanoma | ≥1 % | 55 | 51 |
<1 % | 16 | 6 |
Puzanov et al. [61] | 22C3 | Melanoma (ipilimumab refractory) | ≥1 % | 193 | 26 |
<1 % | 93 | 15 |
Robert et al. [62] | 22C3 | Melanoma | ≥1 % | 896 | NR (PFS HR 0.53) |
<1 % | 197 | NR (PFS HR 0.67–0.76) |
Atezolizumab (MPDL3280A) |
Spigel et al. [63] | SP142 | NSCLC | TC or IC ≥50 % | 53 | 26 |
TC or IC 5–49 % | 84 | 14 |
Spira et al. [20, 64] | SP142 | NSCLC | TC or IC ≥50 % | 24 | 38 |
TC or IC 1–49 % | 69 | 12 |
TC and IC <1 % | 51 | 8 |
Besse et al. [65] | SP142 | NSCLC | TC or IC ≥50 % | 302 | 26 |
TC or IC 5–49 % | 357 | 10 |
Powles et al. [66] | SP142 | Urothelial | TC or IC ≥5 % | 30 | 43 |
TC and IC <5 % | 35 | 11 |
Rosenberg et al. [67] | SP142 | Urothelial | TC or IC ≥5 % | 100 | 26 |
TC and IC 1–5 % | 107 | 11 |
TC and IC <1 % | 103 | 8 |
Herbst et al. [21] | SP142 | Multiple | TC or IC ≥50 % | 33 | 46 |
TC or IC 1–49 % | 57 | 19 |
TC and IC <1 % | 60 | 13 |
Durvalumab (MEDI4736) |
Rizvi et al. [68] | SP263 | NSCLC | ≥25 % | 84 | 27 |
<25 % | 92 | 5 |
Segal et al. [69] | SP263 | HNSCC | ≥25 % | 22 | 18 |
<25 % | 37 | 8 |
Avelumab (MSB0010718C) |
Gulley et al. [70] | ? | NSCLC | ≥5 % | 122 | 15 |
<5 % | 20 | 10 |
Apolo et al. [71] | ? | Urothelial | ≥5 % | 10 | 40 |
<5 % | 22 | 9 |